Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Show drugs work before selling them

Nature volume 543, pages 174–175 (2017)Cite this article

Subjects

Regulation makes economic sense, argue Douglas Sipp, Christopher McCabe and John E. J. Rasko.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Junod, S. W. In A Quick Guide to Clinical Trials (eds Davies, M. & Kerimani, F.) 25–55 (Bioplan, 2008); available at http://go.nature.com/2kjhny4

    Google Scholar 

  2. Da Silva, E. M. K., Strufaldi, M. W. L., Andriolo, R. B. & Silva, L. A. Cochrane Database Syst. Rev. 2, CD008185 (2016).

    PubMed  Google Scholar 

  3. US Food and Drug Administration. 22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results (FDA, 2017); available at http://go.nature.com/2mayug4

  4. Henderson, D. R. 'Markets Can Determine Drug Efficacy' Forbes (8 July 2009); available at http://go.nature.com/2kbkzps

  5. Bothwell, L. E., Greene, J. A., Podolsky, S. H. & Jones, D. S. N. Engl. J. Med. 374, 2175–2181 (2016).

    Article  CAS  Google Scholar 

  6. Moore, T. J. & Furberg, C. D. JAMA Intern. Med. 174, 90–95 (2014).

    Article  Google Scholar 

  7. Siramshetty, V. B. et al. Nucleic Acids Res. 44, D1080–D1086 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Douglas Sipp is a researcher at the RIKEN Center for Developmental Biology in Kobe, Japan, and visiting professor at Keio University School of Medicine and Global Research Institute, Tokyo.,

    Douglas Sipp

  2. Christopher McCabe is a health economist at the University of Alberta, Edmonton, Canada.,

    Christopher McCabe

  3. John E. J. Rasko is head of the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital in Sydney, Australia.,

    John E. J. Rasko

Authors
  1. Douglas Sipp
    View author publications

    Search author on:PubMed Google Scholar

  2. Christopher McCabe
    View author publications

    Search author on:PubMed Google Scholar

  3. John E. J. Rasko
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Douglas Sipp.

Ethics declarations

Competing interests

J.E.J.R. is Director of Pathology and a shareholder at the IVF company Genea. He has a management/advisory relationship with the Cure The Future Foundation (honorary Board Member), FSHD Global Research Foundation (honorary Scientific Patron) and New Directions in Leukaemia Research (honorary Scientific Committee member). He is President-Elect 2016–18 of the International Society for Cellular Therapy, which may have links to companies and affiliations with interests in medical technology development. He chairs the RPA Hospital Institutional Biosafety Committee and has chaired the federal Gene Technology Technical Advisory Committee of the Office of the Gene Technology Regulator, Australian Government, for the past ten years. His Department of Cell & Molecular Therapies is involved in clinical development of gene-modified cells, often in collaboration with companies such as Miltenyi, Terumo, Sillajen, Athersys, Cynata and Novartis. Some or all of these are covered by confidential disclosure agreements. He has had paid consulting relationships and/or travel support, as follows: (i) Honoraria for speaking and/or as part of clinical trials by GSK, Spark, Novartis, bluebird bio; (ii) Rarecyte (past scientific consultant, stocks in lieu); (iii) Imago (scientific consultant). His employer, Sydney Local Health District, NSW Government, assisted with travel as part of his salary package for training education and service leave.

Additional information

Tweet Follow @NatureNews

Related links

Related links

Related links in Nature Research

Boom in unproven cell therapies intensifies regulatory debate 2016-Sep-07

Regulation: Sell help not hope 2014-Jun-16

Don’t market stem-cell products ahead of proof 2013-Jul-17

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sipp, D., McCabe, C. & Rasko, J. Show drugs work before selling them. Nature 543, 174–175 (2017). https://doi.org/10.1038/543174a

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/543174a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing